Nexium drives 7% Consumer growth at Pfizer
Πέμπτη 29 Οκτ 2015
Pfizer said a 7% rise in worldwide sales by its Consumer Healthcare division in the third quarter of 2015 was primarily due to the performance of Nexium 24HR in the US.

Growth had been driven by increased demand for Nexium 24HR, said Pfizer, combined with lower revenues in the same period a year earlier when retailers reduced initial stocking levels following the launch of Nexium 24HR in May 2014.

Reporting its financial results for the third quarter of 2015, Pfizer said Consumer Healthcare had delivered worldwide sales up by 7% on an operational basis to US$817 million. However, a negative currency effect meant sales were flat compared to the same period a year earlier.

Pfizer Consumer Healthcare's sales in its home market of the US increased by 7% to US$442 million, while international sales decreased by 8% as reported to US$375 million. International sales recorded an operational rise of 6%.

Revenues since the launch

Speaking in July 2015, Pfizer's chief executive officer Ian Read said the OTC version of Nexium had generated revenues of approximately US$300 million since its launch, making it one of the largest and most successful prescription-to-OTC switches.

Pfizer acquired exclusive global rights to non-prescription versions of AstraZeneca's Nexium (esomeprazole) in 2012. The deal comprised an upfront payment of US$250 million to AstraZeneca, as well as milestone and royalty payments based on product launches and sales.

The first launch came on 27 May 2014, when Nexium 24HR was introduced in the US as an OTC medicine for frequent heartburn. Since then, Pfizer has launched Nexium Control in a number of European countries including France, Germany, Ireland, Italy, Malta, the Netherlands and the UK.

Consumer Healthcare accounted for 6.8% of Pfizer's total worldwide sales, which were down by 2% as reported to US$12.1 billion in the third quarter of 2015. The operational rise was 6%.

Pfizer said the operational rise reflected a one-month contribution of sales from Hospira, which Pfizer acquired on 3 September 2015. It noted that Hospira was the world's leading provider of injectable drugs and infusion technologies and a global leader in biosimilars.

Does switching and other forms of OTC innovation matter to your company? Take a look at NEW IDEAS BETTER WAYS, the new quarterly OTC Innovations review from the OTCToolbox website (click here to find out more).

Πηγή:  OTC Tool Box

Σχετικά Άρθρα

Κανένα σχόλιο... κάνετε ένα δικό σας σχόλιο

Κάνετε Login για να σχολιάσετε το άρθρο